hims semaglutide & Hers makes deal with Novo in obesity strategy shift Hims & @Hers sees strong

The reported n values therefore correspond to paired vehicle and drug datasets for each mouse, and the plotted intake values reflect one test session per condition per mouse, averaged across mice

This marks Oculis's second ophthalmic drug to enter pivotal studies

Mazdutide Availability Mazdutide received approval in China in 2024 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity

Patients had type 2 diabetes with NO other anti-diabetic agents allowed for at least 90 days prior to the trial

That potential success could drive GLP-1 drug revenues to soar to $400 billion, which is well ahead of some Wall Street estimates that suggests GLP-1 drugs will do only $100 billion in revenue by 2030